Pure Global
NCT06313047

Pharmacogenetic of Doxorubicin in HCC.

Pharmacogenetic of Doxorubicin in Patients With Hepatocellular Carcinoma: A Prospective Cohort Study
Rehab Werida·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatocellular Carcinoma
Drug/Device/Intervention
Doxorubicin
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Rehab Werida
Funder
Damanhour University
Location
Riyadh, Saudi Arabia
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2021
End date
Dec 30, 2023
Enrollment
81 participants
Primary outcome

GSTP1,CYP2B6

Summary

The study included 81 HCC patients, both male and female. Prior to being assessed for
 eligibility, each recruited patient with HCC received a comprehensive review of their medical
 history, physical status, and laboratory results. Every research participant take part in the
 experiment and provided written informed consent.

ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06313047
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06313047 through Pure Global AI's free database. This phase not specified trial is sponsored by Rehab Werida and is currently Completed. The study focuses on Hepatocellular Carcinoma. Target enrollment is 81 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.